• 1.中國人民解放軍總醫(yī)院普通外科（北京100853）;;
  • 2.中國人民解放軍總醫(yī)院第一附屬醫(yī)院燒傷研究所（北京100037）;

目的 　探討性別差異對內(nèi)毒素血癥大鼠肺臟組織核因子-κB（NF-κB）活化的影響。
方法 　取40只清潔級Wistar大鼠，雌、雄各半，分為對照組（雌、雄各10只）和內(nèi)毒素血癥組（雌、雄各10只），采用腹腔注射內(nèi)毒素5 mg/kg制作動物模型，無菌留取肺臟組織標(biāo)本，用凝膠阻滯遷移分析方法（EMSA）檢測NF-κB的活化情況，同時檢測大鼠血清中腫瘤壞死因子-α（TNF-α）及雌二醇（E2）含量。
結(jié)果 　對照組雌、雄性大鼠肺臟組織有NF-κB微弱活化，分別為1.33±0.24和1.47±0.40，同時血清中TNF-α含量較少，分別為(0.75±0.16) ng/ml和(0.82±0.12) ng/ml，各項指標(biāo)在雌、雄性大鼠間差異無統(tǒng)計學(xué)意義（P＞0.05）； 注射內(nèi)毒素后雌、雄性大鼠的NF-κB值分別為12.10±2.89和19.53±2.12，TNF-α值分別為（4.10±0.72） ng/ml和（6.37±1.29) ng/ml，較對照組明顯升高（P＜0.01），但是雌性大鼠各項指標(biāo)的變化明顯低于雄性大鼠（P＜0.01）。對照組雌、雄性大鼠血清E2水平分別為（5.94±1.03) ng/L和(0.93±0.30) ng/L，注射內(nèi)毒素后相應(yīng)值為（6.13±1.31) ng/L和（1.06±0.26） ng/L，但兩組間差異無統(tǒng)計學(xué)意義（P gt;0.05）。
相關(guān)分析表明，雌、雄性內(nèi)毒素血癥大鼠肺臟組織NF-κB 的活化與血清中TNF-α含量呈正相關(guān)（r=0.921 1，P=0.013； r=0.907 2，P=0.017），與E2含量呈負相關(guān)（r=-0.887 5，P=0.017； r=-0.872 3，P=0.022）。
結(jié)論 　內(nèi)毒素血癥大鼠肺臟組織NF-κB的活化及血清中TNF-α的含量存在性別差異，內(nèi)源性雌激素可能通過抑制NF-κB 的活化介導(dǎo)了對雌性內(nèi)毒素血癥大鼠肺臟的保護作用。

引用本文： 杜曉輝,李榮,徐迎新,姚詠明,申傳安,尹會男. 性別差異對內(nèi)毒素血癥大鼠肺臟組織核因子-κB活化的影響. 中國普外基礎(chǔ)與臨床雜志, 2007, 14(1): 53-55. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1.
2. 　Abraham E. Nuclear factor-kappa B and its role in sepsis-associated organ failure [J]. J Infect Dis， 2003; 187 Suppl 2∶S364.
3. 　Schroder J, Kahlke V, Staubach KH, et al. Gender differences in human sepsis [J]. Arch Surg， 1998; 133(11)∶1200.
4. 　Yang H, Young DW, Gusovsky F, et al. Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1 [J]. J Biol Chem， 2000; 275(27)∶20861.
5. 　Knoferl MW, Diodato MD, Angele MK, et al. Do female sex steroids adversely or beneficially affect the depressed immune responses in males after trauma-hemorrhage? [J]. Arch Surg， 2000; 135(4)∶425.
6. 　Gould IM, MacKenzie FM. The response of Enterobacteriaceae to beta-lactam antibiotics——‘round forms, filaments and the root of all evil’ [J]. J Antimicrob Chemother， 1997; 40(4)∶495.
7. 　Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group [J]. Crit Care Med， 1995; 23(6)∶994.
8. 　Hassouna H, Quinn C. Proteolysis of protein C in pooled normal plasma and purified protein C by activated protein C (APC) [J]. Biophys Chem， 2002; 95(2)∶109.
9. 　Mitteregger R, White A, Weber C, et al. In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment [J]. Ther Apher， 1999; 3(3)∶257.
  1. 1.
  2. 2. 　Abraham E. Nuclear factor-kappa B and its role in sepsis-associated organ failure [J]. J Infect Dis， 2003; 187 Suppl 2∶S364.
  3. 3. 　Schroder J, Kahlke V, Staubach KH, et al. Gender differences in human sepsis [J]. Arch Surg， 1998; 133(11)∶1200.
  4. 4. 　Yang H, Young DW, Gusovsky F, et al. Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1 [J]. J Biol Chem， 2000; 275(27)∶20861.
  5. 5. 　Knoferl MW, Diodato MD, Angele MK, et al. Do female sex steroids adversely or beneficially affect the depressed immune responses in males after trauma-hemorrhage? [J]. Arch Surg， 2000; 135(4)∶425.
  6. 6. 　Gould IM, MacKenzie FM. The response of Enterobacteriaceae to beta-lactam antibiotics——‘round forms, filaments and the root of all evil’ [J]. J Antimicrob Chemother， 1997; 40(4)∶495.
  7. 7. 　Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group [J]. Crit Care Med， 1995; 23(6)∶994.
  8. 8. 　Hassouna H, Quinn C. Proteolysis of protein C in pooled normal plasma and purified protein C by activated protein C (APC) [J]. Biophys Chem， 2002; 95(2)∶109.
  9. 9. 　Mitteregger R, White A, Weber C, et al. In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment [J]. Ther Apher， 1999; 3(3)∶257.